Rigel Pharmaceuticals (RIGL) Current Deferred Revenue (2016 - 2025)
Rigel Pharmaceuticals (RIGL) has 15 years of Current Deferred Revenue data on record, last reported at $1.4 million in Q3 2025.
- For Q3 2025, Current Deferred Revenue changed 0.0% year-over-year to $1.4 million; the TTM value through Sep 2025 reached $1.4 million, changed 0.0%, while the annual FY2024 figure was $1.4 million, 0.0% changed from the prior year.
- Current Deferred Revenue reached $1.4 million in Q3 2025 per RIGL's latest filing, roughly flat from $1.4 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $9.5 million in Q1 2021 and bottomed at $1.4 million in Q2 2023.
- Average Current Deferred Revenue over 5 years is $2.2 million, with a median of $1.4 million recorded in 2023.
- Peak YoY movement for Current Deferred Revenue: surged 362.74% in 2021, then crashed 77.93% in 2022.
- A 5-year view of Current Deferred Revenue shows it stood at $2.6 million in 2021, then tumbled by 47.27% to $1.4 million in 2022, then decreased by 1.02% to $1.4 million in 2023, then changed by 0.0% to $1.4 million in 2024, then changed by 0.0% to $1.4 million in 2025.
- Per Business Quant database, its latest 3 readings for Current Deferred Revenue were $1.4 million in Q3 2025, $1.4 million in Q2 2025, and $1.4 million in Q1 2025.